

BORTEZOMIB

BRAND NAME	VELCADE, BORTEZOMIB ACCORD, DBL, JUNO, SANDOZ, TEVA
DRUG CLASS	Cytotoxic antineoplastic, proteasome inhibitor
AVAILABILITY	Vial contains 1 mg, 2.5 mg, 3 mg or 3.5 mg of bortezomib. Also contains mannitol. ¹

WARNINGS	Cytotoxic. Strict handling precautions are required. Bortezomib is an irritant. ^{1,2} Not for intrathecal administration – contraindicated, may be fatal. ¹
----------	---

pH 2–6.5¹

PREPARATION **In a cytotoxic drug safety cabinet:**
For SUBCUT use: reconstitute the vial with sodium chloride 0.9% to make a concentration of 2.5 mg/mL:¹

Vial size	Volume of sodium chloride 0.9% to make 2.5 mg/mL
2.5 mg	1 mL
3 mg	1.2 mL
3.5 mg	1.4 mL

For IV use: reconstitute the vial with sodium chloride 0.9% to make a concentration of 1 mg/mL:¹

Vial	Volume of sodium chloride 0.9% to make 1 mg/mL
1 mg	1 mL
2.5 mg	2.5 mL
3 mg	3 mL
3.5 mg	3.5 mL

The solution is clear and colourless.¹

STABILITY Vial: store below 25 °C. Protect from light.¹
Reconstituted solution: stable for 8 hours at 25 °C or at 2 to 8 °C.¹ Longer stability information is available.^{1,3}

ADMINISTRATION
IM injection Not recommended
SUBCUT injection Inject into the thigh or abdomen. Rotate the site of injection.¹ If injection site reactions occur, use a 1 mg/mL dilution or change to IV administration.¹
IV injection Inject over 3 to 5 seconds through a peripheral or central venous catheter.¹
IV infusion Not recommended

COMPATIBILITY Sodium chloride 0.9%¹

INCOMPATIBILITY No information

SPECIAL NOTES Low emetogenic risk.⁴ Check your local guidelines for premedication requirements.
Give doses of bortezomib at least 72 hours apart.¹

REFERENCES

- Product information. Available from www.tga.gov.au. Accessed 29/03/2022.
- Clinical resource: Extravasation Management [v4 2019]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from www.eviq.org.au. Accessed 29/03/2022.
- McEvoy GK editor. Handbook on injectable drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018.
- Clinical resource: Prevention of antineoplastic induced nausea and vomiting [v5 May 2021]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from www.eviq.org.au. Accessed 29/03/2022.